TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference

Stock News

Yesterday

TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106629682"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106629682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106629682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106629682","market":"fut","top_or_hot":-1,"title":"TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1106629682","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106629682","pubTimestamp":1774449860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","159992":"创新药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","06978":"永泰生物-B","02410":"同源康医药-B","BK1574":"生物医药B类股"},"translate_title":"TYK MEDICINES-B将在2026年AACR会议上展示五个新药项目的研究结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"159992":1,"09939":1,"02410":1,"06978":1},"content_text":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}